Signum Biosciences, Inc.

Sabinsa Corporation

Sami Labs Limited

Keshava Rapole

Michael Voronkov

Jeffry B Stock

Maxwell Stock

Seung-Yub Lee

Eduardo Perez

Joel Gordon

Shuyi Chen

Jinglong Chen

Muhammed Majeed

Kalyanam Nagabhushanam

Ravikrishna Chebolu

Rajendran Ramanujam

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Isoprenyl compounds and methods thereof

Isoprenyl compounds

Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).

Cysteinyl compounds, compositions and methods of use

A process for the manufacture of &#x3b1;-Difluoromethylornithine, analogs and derivatives is described from ornithine hydrochloride or from N-phthaloyl ornithine hydrochloride, conversion to an alkyl ester, conversion to solid derivatives through the formation of Schiff bases, subsequent halomethylation using suitable bases and hydrolysis.

Convenient process of manufacture for difluoromethylornithine and related compounds

Convenient processes are described for the synthesis of L-Se-methyselenocysteine from chloroalanine derivatives. The process is easily extendable to other selenium substituted amino acids. DL-Se-methyselenocysteine is easily obtained by a benzaldehyde-catalyzed racemization of L-Se-methyselenocysteine.

Manufacturing processes for Se-methyl-L-selenocysteine

Growing community of inventors

Edison, NJ, United States of America

Keshava Rapole